| Cat. No. |
Product Name |
Information |
| PC-43463 |
Ki16425
LPA1/LPA3 antagonist
|
Ki16425 (Debio 0719) is a potent, subtype-selective, competitive antagonist of lysophosphatidic acid receptor LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, shows no activity at LPA4, LPA5, LPA6. |
| PC-43245 |
S1P1 Agonist 8
S1P1 agonist
|
S1P1 Agonist 8 is a potent, selective, orally bioavailable S1P1 receptor agonist with EC50 of 35 nM (S1P1 internalization), >100-fold selectivity over against receptor subtypes S1P2-5. |
| PC-43209 |
Etrasimod
S1P1 antagonist
|
Etrasimod (APD334) is a potent, selective, centrally available S1P1 receptor antagonist with β-arrestin EC50 of 6.1 nM, internalizes human S1P1 in CHO cells expressing HA tagged S1P1 with IC50 of 1.88 nM. |
| PC-43000 |
Siponimod
S1P1/S1P5 modulator
|
Siponimod (BAF312) is a potent, selective S1P1/S1P5 receptor modulator with EC50 of 0.39/0.0.98 nM, >1,000-fold selectivity over S1P2/3/4. |
| PC-63010 |
W146
S1P1 antagonist
|
W146 is a potent, selective S1P1 antagonist with Ki of 18 nM, displays no effect at S1P2, S1P3 or S1P5, enhances capillary leakage and restores lymphocyte egress in vivo. |
| PC-63009 |
CYM5442
S1P1 agonist
|
CYM 5442 is a potent and selective S1P1 agonist with EC50 of 1.35 nM. |
| PC-62670 |
ONO-9780307
LPA1 inhibitor
|
ONO-9780307 is a potent, specific lysophosphatidic acid receptor 1 (LPA1) inhibitor with IC50 of 27 nM. |
| PC-62669 |
ONO-9910539
LPA1 antagonist
|
ONO-9910539 is a potent LPA1 receptor inhibitor with IC50 of 22 nM. |
| PC-62668 |
ONO-3080573
LPA1 antagonist
|
ONO-3080573 is a potent LPA1 receptor inhibitor with IC50 of 11 nM. |
| PC-61604 |
GSK1842799
S1P1 agonist
|
GSK1842799 is a potent, selective, oral bioavailable S1P1 agonist with bind affinity of 0.52 nM. |
| PC-70243 |
Ceralifimod
S1P1/S1P5 agonist
|
Ceralifimod (ONO-4641, MSC-2430913A) is a next-generation S1P receptor agonist selective for S1P1 and S1P5 with EC50 of 0.0273 nM and 0.334 nM. |
| PC-61179 |
NIBR0213
S1P1 antagonist
|
NIBR0213 is a potent, selective, orally active S1P1 antagonist with IC50 of 2.5 nM Ca2+ mobilization assays, without activity on S1P2, S1P3 and S1P4 (IC50>10 uM). |
